



3 May 2023

Second Court Hearing Update

Health House International Limited (**ASX:HHI**) (**Health House** or **the Company**) advises the second Supreme Court of Western Australia (**Court**) hearing in relation to the Scheme has been rescheduled for 4.00pm (WST) on Thursday 4 May 2023 (**Second Court Hearing**).

Indicative timetable

The expected key dates for the Scheme are set out below:

Event	Week ending
Second Court Hearing for approval of the Scheme	4.00pm (AWST) on 4 May 2023
Effective Date on which the Scheme comes into effect and is binding Court order lodged with ASIC and announcement to the ASX Last day of trading in Health House Shares on the ASX (with Health House Shares suspended from close of trading)	5 May 2023
Record Date for determining entitlements to Scheme Consideration	5:00 pm (AWST) on 9 May 2023
Implementation Date Payment of Scheme Consideration to be made to Scheme Shareholders	16 May 2023

All dates and times are indicative only and subject to necessary approvals from the Court and each other condition precedent to the Scheme being satisfied or waived. Health House has the right to vary the timetable detailed above subject to the approval of such variation by ASX, the Court and ASIC where required. Any changes to the above timetable will be announced to ASX and notified on the Health House website at <https://healthhouse.com.au/>

Tim Slate

Company Secretary

About Health House (www.healthhouse.com.au)

Health House International and the entities it controls (**the Group**) is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences the Company supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe. The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.

Address

Level 3, 101 St Georges Tce
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: admin@healthhouse.com.au
W: www.healthhouse.com.au
ACN 149 197 651

Contact:

David Wheeler
David@pathwayscorporate.com.au

Tim Slate
Tim.Slate@healthhouse.com.au

Tuesday, 14 December 2021

[illegible]